scispace - formally typeset
Open AccessJournal ArticleDOI

Search-and-replace genome editing without double-strand breaks or donor DNA

Reads0
Chats0
TLDR
A new DNA-editing technique called prime editing offers improved versatility and efficiency with reduced byproducts compared with existing techniques, and shows potential for correcting disease-associated mutations.
Abstract
Most genetic variants that contribute to disease1 are challenging to correct efficiently and without excess byproducts2-5. Here we describe prime editing, a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a catalytically impaired Cas9 endonuclease fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit. We performed more than 175 edits in human cells, including targeted insertions, deletions, and all 12 types of point mutation, without requiring double-strand breaks or donor DNA templates. We used prime editing in human cells to correct, efficiently and with few byproducts, the primary genetic causes of sickle cell disease (requiring a transversion in HBB) and Tay-Sachs disease (requiring a deletion in HEXA); to install a protective transversion in PRNP; and to insert various tags and epitopes precisely into target loci. Four human cell lines and primary post-mitotic mouse cortical neurons support prime editing with varying efficiencies. Prime editing shows higher or similar efficiency and fewer byproducts than homology-directed repair, has complementary strengths and weaknesses compared to base editing, and induces much lower off-target editing than Cas9 nuclease at known Cas9 off-target sites. Prime editing substantially expands the scope and capabilities of genome editing, and in principle could correct up to 89% of known genetic variants associated with human diseases.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

TL;DR: This work analyzes key considerations when choosing genome editing agents and identifies opportunities for future improvements and applications in basic research and therapeutics.

Therapeutic genome editing: prospects and challenges

TL;DR: Current progress toward developing programmable nuclease–based therapies as well as future prospects and challenges are discussed.
Journal ArticleDOI

The promise and challenge of therapeutic genome editing

Jennifer A. Doudna
- 12 Feb 2020 - 
TL;DR: The scientific, technical and ethical aspects of using CRISPR technology for therapeutic applications in humans are discussed, highlighting both opportunities and challenges of this technology to treat, cure and prevent genetic disease.
Journal ArticleDOI

Applications of CRISPR–Cas in agriculture and plant biotechnology

TL;DR: The most important applications of CRISPR-Cas in increasing plant yield, quality, disease resistance and herbicide resistance, breeding and accelerated domestication, and prospective applications of this game-changing technology are discussed.
References
More filters

Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA

TL;DR: The crystal structure of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA at 2.5 Å resolution and accompanying functional analyses have revealed the molecular mechanism of RNA-guided DNA targeting by Cas9, paving the way for the rational design of new, versatile genome-editing technologies.
Journal ArticleDOI

Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements

TL;DR: It is shown that DNA breaks introduced by single-guide RNA/Cas9 frequently resolved into deletions extending over many kilobases, and the observed genomic damage in mitotically active cells caused by CRISPR–Cas9 editing may have pathogenic consequences.
Journal ArticleDOI

Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining

TL;DR: In this article, the authors targeted DNA ligase IV, a key enzyme in the NHEJ pathway, using the inhibitor Scr7, which increased the efficiency of HDR-mediated genome editing, using Cas9 in mammalian cell lines and in mice for all four genes examined.
Journal ArticleDOI

Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells

TL;DR: E1B55K and E4orf6 improved the efficiency of HDR up to eightfold and essentially abolished NHEJ activity in both human and mouse cell lines and provide useful tools to improve the frequency of precise gene modifications in mammalian cells.
Journal ArticleDOI

Base editing: precision chemistry on the genome and transcriptome of living cells

TL;DR: A comprehensive account of the state of the art of base editing of DNA and RNA is provided, including the progressive improvements to methodologies, understanding and avoiding unintended edits, cellular and organismal delivery of editing reagents and diverse applications in research and therapeutic settings.
Related Papers (5)